Merck & Co hires adviser to divest Italian research center
UK-based PharmaVentures has been engaged by US drug major Merck & Co to advise and assist in divesting its world-class research center, the IRBM, located near Rome, Italy. The engagement will utilize PharmaVentures' pharmaceutical transactions experience in the health care and investment business sectors.
The IRBM is an integrated, state-of-the-art, small-molecule and biological discovery center. It has a record of drug discovery including Isentress (raltegravir), the first approved HIV integrase inhibitor and winner of the Prix Galien USA 2008 award for the best pharmaceutical agent. The center has received significant investment since 2000 and is staffed with exceptional, experienced pharmaceutical scientists, according to PharmaVentures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze